GLAXO U.S. IMITREX SALES ARE $87 MIL. THROUGH SIX MONTHS
Executive Summary
GLAXO U.S. IMITREX SALES ARE $87 MIL. THROUGH SIX MONTHS ended Dec. 31, the company reported Feb. 17. The injectable migraine treatment sumatriptan was launched in the U.S. in March. Worldwide sales of the injectable and oral forms of the drug reached $170 mil. ((British Pound)113 mil.), Glaxo reported. The drug now accounts for 4% of Glaxo sales worldwide.